2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Checkpoint Inhibitor, Workforce, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3592 Phase II study of nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in pediatric, adolescent, and young adult patients

Emily Ward, MD, Avinash Ramkissoon, MD2, Batool Al Qanber, MD3, Sairah Ahmed, MD4, Chijioke C Nze, MD, MPH5, Branko Cuglievan, MD6, Amber Gibson, DO7, Cesar Nunez, MD8, Samanta Catueno, MD9, Miriam B. Garcia, DO10, David McCall, MD11
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Classical Hodgkin lymphoma (cHL) is a malignant neoplasm of lymphoid tissue characterized by CD30-positive Hodgkin Reed-Sternberg cells within an inflammatory background. Early-stage (Ann Arbor stage I/II) non-bulky disease is traditionally treated with combined-modality therapy. While adults are most often treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), in pediatric populations, frontline regimens commonly include doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE-PC) or doxorubicin, vincristine, prednisone and cyclophosphamide (AV-PC). Although these approaches achieve excellent outcomes, they may be associated with substantial acute and long-term toxicities, including bleomycin-related pulmonary injury and late effects associated with radiation therapy for slow or inadequate responders. Consequently, treatment de-escalation strategies have focused on maintaining disease control while reducing treatment-related morbidity.  
Nivolumab, an anti-PD-1 monoclonal antibody, combined with doxorubicin, vinblastine, and dacarbazine (Nivo-AVD), has demonstrated promising efficacy (2-year progression free survival (PFS) of 92%) and tolerability in advanced cHL (stage III/IV) and represents a potential strategy to reduce exposure to radiation and eliminate bleomycin. In early-stage disease (I/II), the incorporation of nivolumab into frontline treatment approaches in adults has also produced high response rates with radiation (Nivo-AVD-radiation 41-month PFS of 98-100%) and also without planned radiation (brentuximab vedotin, nivolumab , doxorubicin, dacarbazine (AN-AD), 2-year PFS was 97%) with favorable tolerability. Building on these findings, we are evaluating Nivo-AVD as a frontline regimen for pediatric, adolescent, and young adult patients with newly diagnosed early-stage non-bulky cHL.

 

Methods: This ongoing phase II, open-label, single-arm clinical trial (NCT07551583) is evaluating the safety and preliminary efficacy of Nivo-AVD in patients aged 12 to 21 years with newly diagnosed early-stage (I/II), non-bulky (<10 cm) classical Hodgkin lymphoma. B-symptoms, favorable, and unfavorable subpopulations are eligible. Ongoing preliminary safety assessments will be reviewed to determine the feasibility of lowering the minimum eligible age through a protocol amendment. Treatment consists of Nivo-AVD administered on days 1 and 15 of 28-day cycles using a response-adapted approach. Positron emission tomography (PET) imaging is performed after two cycles and at completion (4 or 6) cycles of therapy. Patients achieving a complete metabolic response following the second cycle will receive a total of four cycles of treatment, while patients with residual, but not progressive FDG-avid disease, will receive a total of six cycles. Radiation therapy is not planned as part of protocol-directed treatment. Up to 15 evaluable patients will be enrolled, with follow-up extending through 2 years after completion of therapy.

 

The primary objectives are to evaluate the safety of Nivo-AVD and to assess preliminary clinical efficacy as measured by overall response rate (ORR). Safety assessments include the incidence, severity, and attribution of adverse events. Secondary objectives include duration of response (DOR), relapse-free survival (RFS), and overall survival (OS).

 

Discussion: This study is designed to evaluate a radiation- and bleomycin-sparing frontline treatment strategy for early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. If feasible and effective, Nivo-AVD may provide an opportunity to maintain excellent disease control while reducing treatment-related toxicities associated with conventional multi-agent chemotherapy and radiation-based approaches.

 

This study is actively recruiting participants at The University of Texas MD Anderson Cancer Center, and accrual is ongoing.
Emily Ward, MD: No relevant conflicts of interest to declare.